Lyo Container Closure Systems

Lyo Container Closure Systems

Container Closure Systems for Freeze-Dried Products

Assessing the impact of container closure systems on primary drying efficiency and lyophilized drug product quality

Container closure systems (CCS) play an essential role in maintaining drug product quality over time. For freeze-dried products, the CCS can also affect the heat and mass transfer during lyophilization and the ultimate primary drying efficiency. As a result, the CCS plays an important role in product quality and process selection. If the CCS is changed, additional adjustments in the freeze-drying process may be required to optimize the drug product. 

In this study, a systematic evaluation was conducted to understand how container closure system variables affect lyophilization formulation characteristics and freeze-drying process parameters. In addition, the vial position in the  freeze-dryer was considered in terms of its potential risk on process failure with different CCS. The evaluated CCS variables were glass vial dimensions and manufacturer, while the evaluated formulation variables were concentration of biologic drug substance, total solid content, and fill height. In addition, freezing process such as conventional freezing or controlled ice nucleation and primary drying parameters were studied in the context of the potential risk to process and product failure. The results revealed that changing the CCS of freeze-dried products without adjustments  in the freeze-drying process parameters may lead to a loss in process efficiency and product quality.  

Assessment of lyophilization primary drying efficiency and container closure systems

Lyophilized samples in two glass vials with different heat transfer parameters were investigated with multi-scale XRM imaging.   


Non-Invasive, Quantitative Characterization of Lyophilized Drug Product Using 3D XRM Analytics

Drug Development and Delivery Paper in collaboration with BMS and Moderna

Non-invasive 3D X-Ray microscopy imaging technique for quantitative characterization of lyophilized drug product

IFPAC 2021 Presentation in collaboration with Dr. Maxwell Korang-Yeboah from the FDA

Assessing the risk of changes in container closure system of a freeze-dried product on primary drying efficiency and product quality

IFPAC 2021 Presentation by Dr. Maxwell Korang-Yeboah from the FDA featuring DigiM analysis